Announcements
- Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
- Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
- Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
- Axogen, Inc Reports First Quarter 2024 Financial Results
- Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
- Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
- Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
- Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
- Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
- Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
More ▼
Key statistics
On Friday, AxoGen Inc (0HKD:LSE) closed at 6.81, 94.45% above the 52 week low of 3.50 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 6.81 |
Average volume | 125.89 |
---|---|
Shares outstanding | 43.70m |
Free float | 39.87m |
P/E (TTM) | -- |
Market cap | 298.50m USD |
EPS (TTM) | -0.4943 USD |
Data delayed at least 20 minutes, as of May 31 2024 17:04 BST.
More ▼